Gland Pharma Ltd stock (INE025W01027): USFDA nod for glaucoma drug lifts shares in India

Gland Pharma Ltd shares rose after the company received USFDA approval for its Latanoprostene Bunod ophthalmic solution, a glaucoma drug, in late April 2026.

Gland Pharma Ltd shares have gained traction in Indian markets after the company announced USFDA approval for its Latanoprostene Bunod Ophthalmic Solution, 0.024%, a generic glaucoma treatment, in late April 2026. The approval, granted under an Abbreviated New Drug Application (ANDA), expands Gland Pharma’s presence in the U.S. ophthalmic market and supports its strategy of growing specialty injectables and ophthalmic products abroad, according to India Infoline as of April 30, 2026.

On the National Stock Exchange of India, Gland Pharma’s stock traded around ?1,904.40 on May 8, 2026, reflecting a roughly 10.5% gain over the prior month, according to Tickertape as of May 8, 2026. The stock’s performance has outpaced the broader Nifty Pharma index, which rose about 1.6% over the same period, underscoring investor interest in the company’s regulatory milestones and pipeline progress, per the same source.

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Gland Pharma Ltd
• Sector/industry: Pharmaceuticals & Biotechnology
• Headquarters/country: Hyderabad, India
• Core markets: India, United States, Europe and other emerging markets
• Key revenue drivers: Small volume parenterals (SVPs), contract development and manufacturing services, ophthalmic products
• Home exchange/listing venue: National Stock Exchange of India (NSE: GLAND)
• Trading currency: Indian rupee (?)

Gland Pharma Ltd: core business model

Gland Pharma Ltd is an Indian specialty pharmaceutical company focused on manufacturing small volume parenterals (SVPs), which are injectable drugs used in hospitals and clinics for conditions such as pain management, oncology and critical care. The company also provides contract development and manufacturing services to global pharmaceutical firms, helping them scale injectable products from clinical to commercial stages, according to Tickertape as of May 8, 2026.

The company’s business model centers on high?barrier?to?entry injectables, where regulatory complexity and manufacturing expertise create a competitive moat. Gland Pharma’s facilities are designed to meet stringent quality standards required by the U.S. Food and Drug Administration (USFDA) and other global regulators, enabling it to supply generic injectables and specialty products to markets such as the United States and Europe, per the same source.

For US investors, Gland Pharma offers indirect exposure to the global injectables and ophthalmic markets through its Indian listing and its role as a contract manufacturer and generic supplier to international brands. The company’s ability to secure approvals like the recent Latanoprostene Bunod ANDA highlights its relevance in the broader U.S. generics and specialty pharma ecosystem, even though its primary listing remains in India.

Main revenue and product drivers for Gland Pharma Ltd

Gland Pharma’s main revenue streams come from small volume parenterals, contract development services and an expanding portfolio of ophthalmic products. The company is recognized as a leading player in the global pemetrexed market, an injectable chemotherapy agent, and features among the top 30 companies in that segment, according to Spherical Insights as of 2026.

The recent USFDA approval for Latanoprostene Bunod Ophthalmic Solution, 0.024%, adds a branded?generic ophthalmic product to Gland Pharma’s U.S. portfolio. Latanoprostene Bunod is used to reduce intraocular pressure in patients with open?angle glaucoma or ocular hypertension, a large and growing therapeutic area driven by aging populations in the United States and Europe, according to India Infoline as of April 30, 2026.

Analysts note that Gland Pharma’s small?cap classification within the Indian pharmaceuticals sector implies higher volatility but also potential for growth if the company continues to win regulatory approvals and expand its contract manufacturing footprint, according to MarketsMOJO as of May 4, 2026. The stock’s year?to?date return of about 1.7% in 2026, versus a negative return for the Sensex, reflects investor optimism around its pipeline and U.S. market access, per the same source.

Why Gland Pharma Ltd matters for US investors

For US investors, Gland Pharma matters as a supplier and contract manufacturer to the U.S. healthcare system, even though its shares trade on Indian exchanges. The company’s injectable and ophthalmic products are used in U.S. hospitals and clinics, and its USFDA?approved facilities position it as a potential partner for American and European pharmaceutical firms seeking outsourced manufacturing capacity, according to Tickertape as of May 8, 2026.

The glaucoma drug approval also underscores the importance of Indian generic manufacturers in the U.S. ophthalmic market, where cost?effective alternatives to branded therapies are in demand. As U.S. payers and providers seek lower?cost options, companies like Gland Pharma can benefit from increased demand for generic injectables and ophthalmic solutions, according to India Infoline as of April 30, 2026.

US investors interested in global pharma exposure may view Gland Pharma as a way to tap into growth in emerging?market manufacturing and specialty injectables, while remaining mindful of currency, regulatory and geopolitical risks associated with Indian equities, per the same source.

Conclusion

Gland Pharma Ltd has gained attention after receiving USFDA approval for its Latanoprostene Bunod Ophthalmic Solution, 0.024%, a generic glaucoma treatment, in late April 2026. The approval supports the company’s strategy of expanding its U.S. ophthalmic and injectable portfolio and has contributed to positive share?price momentum in Indian markets, according to India Infoline as of April 30, 2026 and Tickertape as of May 8, 2026.

The company’s focus on small volume parenterals, contract development services and specialty ophthalmic products positions it as a niche player in the global generics and injectables space. For US investors, Gland Pharma offers indirect exposure to U.S. healthcare demand through its manufacturing and supply relationships, even though its primary listing is in India.

Investors should weigh the potential benefits of regulatory milestones and pipeline growth against the risks of currency fluctuations, regulatory scrutiny and competitive pressures in the Indian and global pharmaceutical markets. This article does not constitute investment advice; stocks are volatile financial instruments and past performance is not indicative of future results.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.